**From:** "Kevin Outterson" <Kevin.Outterson@mail.wvu.edu>
**To:** <drugpricing@ita.doc.gov>
**Date:** 6/23/04 11:33AM
**Subject:** Submissions for MMA 2003 section 1123 study

Per the notice in the Federal Register [Federal Register: June 1, 2004 (Volume 69, Number 105)
Page 30882-30883], I submit the following documents for consideration in the study required under section 1123 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

I am willing to testify on the following topics:

1. The effect on pricing and innovation of drug importation from Canada and other OECD nations

2. The role of patents and TRIPS in drug innovation, including parallel trade (exhaustion rules) and non-patent marketing exclusivity rules (Hatch-Waxman, etc)

3. TRIPS Plus trade agreements, particularly the US-Australian FTA and its effect on Australia's PBS (a form of internal reference pricing with value-based economic evaluation).

4. State efforts to implement reference pricing.

I have attached a few of my recent articles. You need to hear from a few people who are not funded by PhRMA on these issues.

Best wishes,

Kevin Outterson

Associate Professor of Law
West Virginia University
304 293 8282
kevin.outterson@mail.wvu.edu
LL.M. (Cantab.)
J.D. (Northwestern)
SSRN Author Page: ssrn.com/author=340746